Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 229

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 229
---
 and management plans: |

The Company
is in the research and development (R&D) stage and, as such, has not generated any revenues from its current operations. The Company’s
activities are primarily funded through the proceeds of private placement of its securities. As of June 30, 2025, the Company reported
an accumulated deficit of $13,119.

To support
its operations and advance its development programs, the Company intends to continue securing investments from qualified investors. Management
anticipates that additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring
healthcare or healthcare-related technologies. However, there are currently no binding commitments for further investment, and there
can be no assurance that the Company will secure the required capital on commercially reasonable terms, or at all.

If sufficient
investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain
development programs. Despite these potential challenges, management believes that the Company’s existing financial resources will
be sufficient to sustain its planned operations for at least the next twelve months.

<div align='center'>F-39</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

| NOTE 1: - | GENERAL (Cont.) |

| NOTE 2: - | SIGNIFICANT ACCOUNTING POLICIES |

These
unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying
notes for the year ended December 31, 2024. The significant accounting policies applied in the annual financial statements of the Company
as of December 31, 2024, are applied consistently in these interim consolidated financial statements.

Following
the closing on July 23, 2024 of the Share Exchange Agreement with Lipovation Ltd. whereby Lipovation Ltd. become a wholly owned subsidiary
of Revium Rx, in accordance with ASC 810, Lipovation’s financial statement are presented as the “Predecessor” for periods
prior to the closing of the acquisition. Revium Rx, which includes consolidation of Lipovation Ltd. subsequent to the acquisition, is
the “Successor” for periods after the closing of the acquisition. As a result of the application of the acquisition method
of accounting in the Successor period, the financial statements for the Successor period are presented on a full step-up basis as a result
of